Provided by Tiger Fintech (Singapore) Pte. Ltd.

SAB Biotherapeutics, Inc.

1.79
+0.03992.28%
Pre-market: 1.810.0600+3.43%09:04 EDT
Volume:32.74K
Turnover:56.43K
Market Cap:16.63M
PE:-0.49
High:1.81
Open:1.71
Low:1.64
Close:1.75
Loading ...

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
01 Apr

SAB Biotherapeutics price target lowered to $20 from $25 at Chardan

TIPRANKS
·
01 Apr

SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024

TIPRANKS
·
31 Mar

Press Release: SAB BIO Reports Full Year 2024 Operating and Financial Results

Dow Jones
·
31 Mar

SAB Biotherapeutics Inc expected to post a loss of $1.16 a share - Earnings Preview

Reuters
·
25 Mar

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
30 Jan

Gold Gains 1%; Boeing Shares Rise Following Q4 Results

Benzinga
·
29 Jan

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

TIPRANKS
·
28 Jan

SAB Biotherapeutics Inc - to Advance SAB-142 Into Phase 2B Trial in 2025

THOMSON REUTERS
·
28 Jan

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

TIPRANKS
·
23 Jan

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

GlobeNewswire
·
23 Jan

These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts

TipRanks
·
15 Nov 2024

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

Simply Wall St.
·
09 Nov 2024

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 Nov 2024

SAB BIO Q3 2024 Cash, Cash Equivalents Available $30.4M-$56.6M

Benzinga
·
07 Nov 2024

SAB Biotherapeutics Inc: Have Cash Sufficient to Fund Its Operations Into 2026

THOMSON REUTERS
·
07 Nov 2024

SAB Biotherapeutics Inc- Qtrly Shr Loss $1.12

THOMSON REUTERS
·
07 Nov 2024

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

GlobeNewswire
·
31 Oct 2024